These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 25554212)
21. Effectiveness of the Trima Accel cell separator in the double dose plateletpheresis. Keklik M; Korkmaz S; Kalan U; Sarikoc M; Keklik E Transfus Apher Sci; 2016 Oct; 55(2):240-242. PubMed ID: 27522105 [TBL] [Abstract][Full Text] [Related]
22. Effect of Mirasol pathogen reduction technology system on in vitro quality of MCS+ apheresis platelets. Mastroianni MA; Llohn AH; Akkök ÇA; Skogheim R; Ødegaard ER; Nybruket MJ; Flesland A; Mousavi SA Transfus Apher Sci; 2013 Oct; 49(2):285-90. PubMed ID: 23820429 [TBL] [Abstract][Full Text] [Related]
23. Collection of hyperconcentrated platelets with Trima Accel. Ringwald J; Duerler T; Frankow O; Zimmermann R; Zingsem J; Strasser E; Antoon M; Eckstein R Vox Sang; 2006 Feb; 90(2):92-6. PubMed ID: 16430666 [TBL] [Abstract][Full Text] [Related]
24. Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets. Charania R; Smith J; Vesely SK; Dale GL; Holter J Transfusion; 2011 Dec; 51(12):2690-4. PubMed ID: 21645004 [TBL] [Abstract][Full Text] [Related]
25. Recruitment of platelets, white blood cells, and hematopoietic progenitor cells during high-yield plateletpheresis. Fontana S; Rados L; Schmid P; Leibundgut EO; Taleghani BM Transfusion; 2011 Sep; 51(9):2034-43. PubMed ID: 21438883 [TBL] [Abstract][Full Text] [Related]
27. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Picker SM; Schneider V; Gathof BS Transfusion; 2009 Jun; 49(6):1224-32. PubMed ID: 19220821 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of the haemonetics MCS cell separator in the collection of apheresis platelets. Keklik M; Keklik E; Korkmaz S; Aygun B; Arik F; Kilic O; Sarikoc M Transfus Apher Sci; 2015 Dec; 53(3):396-8. PubMed ID: 26283175 [TBL] [Abstract][Full Text] [Related]
29. Platelet Recruitment during Multiple Donor Platelet Apheresis Differs between Cell Separators. Fontana S; Keller P; Taleghani BM Transfus Med Hemother; 2011; 38(3):195-198. PubMed ID: 21760764 [TBL] [Abstract][Full Text] [Related]
30. Storage of apheresis platelet concentrates after manual replacement of >95% of plasma with PAS 5. Morrison A; McMillan L; Radwanski K; Blatchford O; Min K; Petrik J Vox Sang; 2014 Oct; 107(3):247-53. PubMed ID: 24801569 [TBL] [Abstract][Full Text] [Related]
31. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Ambruso DR; Thurman G; Marschner S; Goodrich RP Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996 [TBL] [Abstract][Full Text] [Related]
32. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Picker SM; Oustianskaia L; Schneider V; Gathof BS Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416 [TBL] [Abstract][Full Text] [Related]
33. An in vitro pilot study of apheresis platelets collected on Trima Accel system and stored in T-PAS+ solution at refrigeration temperature (1-6°C). Reddoch-Cardenas KM; Sharma U; Salgado CL; Montgomery RK; Cantu C; Cingoz N; Bryant R; Darlington DN; Pidcoke HF; Kamucheka RM; Cap AP Transfusion; 2019 May; 59(5):1789-1798. PubMed ID: 30725491 [TBL] [Abstract][Full Text] [Related]
34. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989 [TBL] [Abstract][Full Text] [Related]
35. The influence of simulated shipping conditions (24- or 30-hr interruption of agitation) on the in vitro properties of apheresis platelets during 7-day storage. Wagner SJ; Vassallo R; Skripchenko A; Einarson M; Seetharaman S; Moroff G Transfusion; 2008 Jun; 48(6):1072-80. PubMed ID: 18373503 [TBL] [Abstract][Full Text] [Related]
36. The role of bicarbonate in platelet additive solution for apheresis platelet concentrates stored with low residual plasma. Radwanski K; Min K Transfusion; 2013 Mar; 53(3):591-9. PubMed ID: 22725609 [TBL] [Abstract][Full Text] [Related]
37. Donor safety in triple plateletpheresis: results from the German and Austrian Plateletpheresis Study Group multicenter trial. Heuft HG; Moog R; Fischer EG; Zingsem J; Transfusion; 2013 Jan; 53(1):211-20. PubMed ID: 22612302 [TBL] [Abstract][Full Text] [Related]
38. Postdonation platelet counts are safe when collecting platelets with the Trima Accel using a postdonation platelet count target of > or =50,000 platelets/microL. Alex J; Roberts B; Raife T J Clin Apher; 2009; 24(5):215-7. PubMed ID: 19816960 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of concurrent collection of in-line filtered platelets and packed red blood cells by multicomponent apheresis with three last-generation apparatuses. Picker SM; Radojska SM; Gathof BS Vox Sang; 2006 Jul; 91(1):47-55. PubMed ID: 16756601 [TBL] [Abstract][Full Text] [Related]
40. Reduced use of allogeneic platelets through high-yield perioperative autologous plateletpheresis and reinfusion. Alberts M; Bandarenko N; Gaca J; Lockhart E; Milano C; Alexander S; Linder D; Lombard FW; Welsby IJ Transfusion; 2014 May; 54(5):1348-57. PubMed ID: 24898456 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]